Last reviewed · How we verify
Chronic Occlusive Peripheral Arterial Disease
Approved treatments
- Nafronyl
Nafronyl works by interacting with the 5-hydroxytryptamine receptor 2A to improve blood flow and reduce vascular resistance. - Praxilene · Merck Serono (originally Lipha)
A 5-HT2 receptor antagonist that improves peripheral blood flow and cellular metabolism by blocking serotonin-mediated vasoconstriction and enhancing aerobic metabolism in ischaemic tissues.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic Occlusive Peripheral Arterial Disease patent landscape — cliff calendar, originator estates, attackable patents
- Chronic Occlusive Peripheral Arterial Disease treatment landscape brief
- Chronic Occlusive Peripheral Arterial Disease treatment updates RSS
Frequently asked questions about Chronic Occlusive Peripheral Arterial Disease
What drugs treat Chronic Occlusive Peripheral Arterial Disease?
Tracked treatments include Nafronyl, Praxilene.
What is the treatment for Chronic Occlusive Peripheral Arterial Disease?
Standard treatment for Chronic Occlusive Peripheral Arterial Disease includes Nafronyl, Praxilene. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic Occlusive Peripheral Arterial Disease patent cliff · Chronic Occlusive Peripheral Arterial Disease CI report
- Treatment: Nafronyl
- Treatment: Praxilene · Merck Serono (originally Lipha)
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing